Search | Search by Center | Search by Source | Keywords in Title
Kramer JR, Richardson PA, Kim H, Hsu YC, Kanwal F, El-Serag HB. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Apr 1; 21(4):1111-1113.e3.
The comparative effectiveness of tenofovir (TDF) vs entecavir (ETV) in reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) remains unclear. Data from a retrospective Korean cohort study published by Choi et al initially suggested a lower-than-expected incidence of HCC in patients on long-term TDF. However, additional studies from Korea did not show a statistically significant difference in HCC incidence rate between TDF and ETV groups, and subsequent studies reported mixed results ranging from no association or a slight advantage for TDF. Most of these studies examined Asian patients from Korea, Taiwan, and China.